Automated detection of aromas has been achieved with limited success using a class of technology known loosely as “e-nose” instruments. These instruments (e.g., the Cyranose commercially available from Cyrano Sciences) employ some form of a sensor array to measure the presence of volatile organic compounds in a gaseous sample. To apply such analyzers to detect the presence of some targeted condition (e.g., an infection in a wound or contamination in a food stock) requires that the components of the condition's aroma signature be known and then gas sample analysis(es) performed to compare the sample's signatures to the known signature.
The technology has only been successful in controlled laboratory environments at least for two reasons. The first reason is that the devices generally operate with a limited, and fixed, number of chemical detectors, each of which must be preselected by fore-knowledge of the chemical composition of the anticipated aromas. This limits the technologies to aromas that are either simple in composition or stable over time. The second reason is that laboratory conditions allow for excluding any confounding background odors from the analysis environment simply by limiting the presence of odor-producing materials. This is clearly not the case for field conditions where odor-producing materials are ubiquitous. The two issues are exacerbated by the use of highly sensitive chemical detectors capable of measuring very small amounts of volatiles in the sample, leading to over emphasis of extraneous compounds in the response or saturation of the detectors when large quantities of their analytes are present.
The consequence of these issues is that c-nose technologies have not been successfully applied to a full range of applications that may be amenable to detection by automated aroma detection. Of particular interest to society are healthcare applications, but these are also the most challenging fur at least the two reasons previously set forth. The multiplicity and time-varying nature of pathophysiologic states, patient co-morbidities, and pharmacologic interventions, which are present in all seriously ill patients, make the targeted aroma signatures very difficult to predetermine. Similarly, the complexity and inter-site variations in environmental aromas make the aromatic signal-to-noise ratio especially challenging.
A publication by Jane Hill and colleagues (see, Jiangjiang Zhu, Heather D. Bean, Yin-Ming Kuo, and Jane E. Hill, J. Clin. Microbiol., 48 (12): 4426-4431, 2010) illustrates the problem when their supplemental material is ethically examined.
Embodiments of the present invention provide conjoint improvements to make automated aroma analysis practical in complex field environments. The promise of automated aroma analysis has never been fully achieved because of the issues of background constituents confounding the limited analytical ranges of fixed-sensor electronic nose technologies. Recognizing that conventional electronic nose technologies utilizing arrays of single-compound sensors are both sensitive to background contaminants and miss as tremendous number of unidentified but potentially didactic constituent compounds in the complex aromas of field samples, described is a novel system of apparatus and methods that compensate for background contaminants while automatically emphasizing all constituents, be they chemically identified or not, which represent information content in the sample under test.
A solution to the foregoing involves three conjoint improvements to the practice of the current art in e-nose methods. A first improvement is to spread the chemical signature analysis into at least one additional dimension to create a two-dimensional (“2D”) odorgram. This confers a benefit of a much more sensitive and specific data set to operate upon. A second improvement is to recognize that the data set is generally an unknown mixture of signal and noise that must be separated by using a noise reference: this may be accomplished here with adaptive noise cancellation algorithms. The science of odor analysis has been so focused on identifying individual chemical analytes in the odor profiles that the question of whether the intervening peaks in a spectrum represent signal or noise has never been effectively investigated. Kwak and Preti (see, Jae Kwak and George Preti, Current Pharmaceutical Biotechnology, 12:1067-1074, 2011) raised the specter of an irreconcilable admixture of signal and noise constituents in odor signatures and implied that it was an intractable problem. It is not. A third improvement is a means to obtain a reference source of merely the contaminating odors, which need be only similar, not identical, to those contaminating the sample itself.
Traditional gas analysis involves some form of serial analysis; gas chromatography and mass spectrometry are well known, although there are many other analytical methods that generate a plot of a swept parameter (e.g., column residence time) and the measured intensity at each value of that parameter. Some of these methods can also be used to fractionate the sample, and that fractionated sample can then be subjected to secondary analyses. When each of these is treated as a value in a characterization vector, an n-dimensional characterization of the sample can be obtained. An example is the use of gas chromatography (“GC”) followed by a differential ion mobility analysis (“GC”) (collectively, “GC-DMS”). A schematic of such an instrument is illustrated in
Examination of the example odorgram in
Looking at just an odorgram, it is difficult to determine a priori which constituents represent a desired signal and which represent contaminants from the environmental background. Kwak and Preti, previously referenced, have illustrated the perniciousness of those contaminants in their critique paper. It is not just the ambient odors at the time the sample is collected, but any contaminants emanating from the subject and not related to the condition that are being tested for. For example, testing the breath of a patient for chemical signals of the onset of pneumonia can be confounded by the analytes absorbed by the patient from vehicle exhaust in route to the testing center. The body odor of human subjects is also a major source of volatile analytes. Currently, analytes can only be rejected as background (i.e., “noise”) if their chemical compounds can be identified as biochemically exogenous to the condition under test.
Further complicating the situation is that many of the constituents that can be detected with analytical instruments have not been identified or are not identifiable. Many such unknown constituents can be seen in the table in
In the event that the desired odorgram of the targeted condition has been previously determined, by laboratory work or careful sampling in simulated field environments, a solution is to employ a correlation of field-acquired samples' odorgrams with the known desired odorgram and report a goodness-of-fit metric to the operator. A method would be the use of cross-correlation between the known odorgram and the field-acquired odorgram(s) to compute a correlation coefficient. Another approach is to use peak-matching or k-nearest-neighbor methods to quantitatively compare the two odorgrams. Prior knowledge of which regions of the odorgram are the most indicative of the target condition and which regions are the most prone to external contaminating constituents may be used to weight the comparisons.
However, determining the desired odorgram of the targeted condition can be quite difficult, because recreations of the desired aromas are likely to not fully represent those found under field circumstances. For example, the use of laboratory-incubated cultures of bacteria as a source of aromas indicative of infections will not be representative of infected wound aromas due to the differences in the bacterial substrates, agar instead of tissue. Further, it is also known that bacteria produce different aromas in different stages of growth, and therefore the odorgram of an early-stage infection may be, but is not assured to be, different from a late-stage infection.
A more complete solution, then, is to find a source of related, but not necessarily identical, constituent “noise” gas and cancel the presence of that noise from the target sample in order to arrive at a pure signal, regardless of its source or circumstance.
Adaptive noise cancellation was introduced by Bernard Widrow in the 1970's at the Naval Research Station in San Diego (see, Widrow et al., “Adaptive noise cancelling: principles and applications,” Proc IEEE, 63 (12):1692-1716, 1975, which is hereby incorporated by reference herein). The signal processing principles he used can be applied to solve the current problem by recognizing that the noise in question can be transformed to a digital domain once the reference source and the sample source gasses are converted to signals by the analyzer. Performed adaptively, this approach removes all components of noise from the final odorgram that are present in the odorgram of the admixture of signal and noise gas constituents.
A schematic of a basic processing flow is illustrated in
Successful application of noise cancellation methods requires a reference source containing as little of the desired signal as possible. To obtain such a reference gas in the field will depend on the specific application to which the odor analyzer is put. In any case, it will require some specific apparatus to be built that will maximally exclude gas from the target source.
Recognizing Kwak and Preti's (see previous reference) objections to typical breath analysis as a valid concern for historical exposure to environmental trace contaminants, embodiments of the present invention utilize one or more of at least two basic solutions for the source of the reference gas. These solutions utilize an attribute of the adaptive noise canceller not requiring an exact copy of the contaminants present in the admixture sample but merely to be representative of those components.
The embodiment illustrated in
The source of reference gas is likely to be abundant (e.g., from the ambient room air) whereas the admixture gas (e.g., drawn from a patient) may be only occasionally available. This is convenient for training the noise rejection transfer function F iteratively by repeatedly sampling the reference gas. The repeated samples of reference gas may be analyzed and used to generate updated versions of the reference odorgram N′ while processing and updating the transfer function F using the singular version of the admixture odorgram S+N. Iteration is often required of adaptation algorithms to cause the transfer function to converge to a stable solution. If serial samples of the reference gas are not available, then the odorgrams N′ and S+N may be synthetically dithered to provide the signal variance required to obtain convergence of the transfer function model.
Retelling to
It is possible to obtain the gas samples in real time or from trapping technologies. Use of a trap is especially advantageous for the reference sample in healthcare applications, as shown in this figure, because it mimics the accumulation of constituent chemicals presented to the individual patient over time and absorbed into their body. These absorbed compounds then are released in odor gas samples along with the markers of pathology that are sought in the test. Without use of a trap travelling with the patient during their daily living, these compounds, which are indeed chemical noise, can be applied at the noise reference input. Without sampling of these compounds, it would appear as if they were generated by the patient, i.e., markers of the pathology being tested for.
This application claims priority to U.S. Provisional Application Ser. No. 61/638,100, which is hereby incorporated by reference herein. This application is related to U.S. Provisional Patent Application Ser. No. 61/583,288 and U.S. Published Application No. 2013/0066349, which are hereby incorporated by reference herein.
Filing Document | Filing Date | Country | Kind |
---|---|---|---|
PCT/US2013/037944 | 4/24/2013 | WO | 00 |
Number | Date | Country | |
---|---|---|---|
61638100 | Apr 2012 | US |